


## PHARMACEUTICAL 2022

Bristol Myers Squibb

## BRISTOL MYERS SQUIBB CO Rank 80 of 475





## PHARMACEUTICAL 2022

Bristol Myers Squibb



## BRISTOL MYERS SQUIBB CO Rank 80 of 475

The relative strengths and weaknesses of BRISTOL MYERS SQUIBB CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BRISTOL MYERS SQUIBB CO compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 261% points. The greatest weakness of BRISTOL MYERS SQUIBB CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 76%, being 352% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	33,262,000
Cost of Goods Sold	9,940,000
Intangible Assets	63,029,000
Liabilities, Current	21,868,000
Liabilities, Non-Current	46,939,000
Other Assets	6,974,000
Other Compr. Net Income	551,000
Other Expenses	10,387,000
Other Liabilities	4,501,000
Other Net Income	0
Property and Equipment	6,049,000
Research and Development	11,354,000
Revenues	46,385,000
Selling, General and Administrative Expense	7,690,000

Output Variable	Value in 1000 USD
Assets	109,314,000
Liabilities	73,308,000
Expenses	39,371,000
Stockholders Equity	36,006,000
Net Income	7,014,000
Comprehensive Net Income	7,289,500
Economic Capital Ratio	76%